Mesantoin Related Published Studies
Well-designed clinical trials possibly related to Mesantoin (Mephenytoin)
Exposure to oral S-ketamine is unaffected by itraconazole but greatly increased by ticlopidine. [2011.08]
Design, baseline characteristics, and retention of African American light smokers into a randomized trial involving biological data. [2011.01.25]
Gene polymorphisms in cyclophosphamide metabolism pathway,treatment-related toxicity, and disease-free survival in SWOG 8897 clinical trial for breast cancer. [2010.12.15]
Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study. [2010.09.01]
Effects of woohwangcheongsimwon suspension on the pharmacokinetics of bupropion and its active metabolite, 4-hydroxybupropion, in healthy subjects. [2010.07]
Double-dosed pantoprazole accelerates the sustained symptomatic response in overweight and obese patients with reflux esophagitis in Los Angeles grades A and B. [2010.05]
Influence of CYP2B6 polymorphisms on the persistence of plasma nevirapine concentrations following a single intra-partum dose for the prevention of mother to child transmission in HIV-infected Thai women. [2009.12]
Kinetics of omeprazole and escitalopram in relation to the CYP2C19*17 allele in healthy subjects. [2008.12]
Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers. [2008.05]
Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation. [2007.08]
Validation of incorporating flurbiprofen into the Pittsburgh cocktail. [2006.09]
Investigation of sarizotan's impact on the pharmacokinetics of probe drugs for major cytochrome P450 isoenzymes: a combined cocktail trial. [2006.04]
Effect of propiverine on cytochrome P450 enzymes: a cocktail interaction study in healthy volunteers. [2005.12]
Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism. [2005.02.01]
Other research related to Mesantoin (Mephenytoin)
Identification of New CYP2C19 Variants Exhibiting Decreased Enzyme Activity in the Metabolism of S-Mephenytoin and Omeprazole. [2009.11]
Other possibly related research studies
Liver disease selectively modulates cytochrome P450--mediated metabolism. [2006.09]
A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. [2006.01]
Pyrosequencing-based screening for genetic polymorphisms in cytochrome P450 2B6 of potential clinical relevance. [2006.10]
Effect of conjugated equine estrogens on oxidative metabolism in middle-aged and elderly postmenopausal women. [2006.11]
Determinants of the rate of nicotine metabolism and effects on smoking behavior. [2006.10]
Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration. [2006.09.15]
Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity. [2006.09.15]
Genotyping of CYP2B6 and therapeutic drug monitoring in an HIV-infected patient with high efavirenz plasma concentrations and severe CNS side-effects. [2006]
Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity. [2006.07]
The pharmacokinetics of escitalopram in patients with hepatic impairment. [2006.01.20]
Overview of the pharmacogenetics of HIV therapy. [2006.07]
Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. [2006.02.01]
Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations. [2005.11]
Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. [2005.12]
Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. [2005.12]
Pharmacogenetics of cyclophosphamide in patients with hematological malignancies. [2006.01]
Influence of genetic polymorphisms of styrene-metabolizing enzymes and smoking habits on levels of urinary metabolites after occupational exposure to styrene. [2005.12.30]
Lack of interaction of milnacipran with the cytochrome p450 isoenzymes frequently involved in the metabolism of antidepressants. [2005]
A tubule cell model for ifosfamide nephrotoxicity. [2005.06]
Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population. [2005.08]
Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation. [2005.06]
Effect of age and postoperative time on cytochrome p450 enzyme activity following liver transplantation. [2005.06]
Cytochrome P450 3A and 2B6 in the developing kidney: implications for ifosfamide nephrotoxicity. [2005.07]
A virus-directed enzyme prodrug therapy (VDEPT) strategy for lung cancer using a CYP2B6/NADPH-cytochrome P450 reductase fusion protein. [2005.05]
Phase I study of MetXia-P450 gene therapy and oral cyclophosphamide for patients with advanced breast cancer or melanoma. [2005.02.15]
A cytochrome P450 2B6 meditated gene therapy strategy to enhance the effects of radiation or cyclophosphamide when combined with the bioreductive drug AQ4N. [2005.07]
Efavirenz intoxication due to slow hepatic metabolism. [2005.02.01]
Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the "cocktail" approach. [2007.02]
Artemisinin antimalarials moderately affect cytochrome P450 enzyme activity in healthy subjects. [2007.06]
Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers. [2007.05]
Does tenofovir influence efavirenz pharmacokinetics? [2007]
Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients. [2007.06]
Cytochrome P450 2B6 is a growth-inhibitory and prognostic factor for prostate cancer. [2007.07.01]
The role of pharmacogenetics in the metabolism of antiepileptic drugs: pharmacokinetic and therapeutic implications. [2007]
Involvement of CYP2A6 in the formation of a novel metabolite, 3-hydroxypilocarpine, from pilocarpine in human liver microsomes. [2007.03]
Genetic variability of CYP2B6 polymorphisms in four southern Chinese populations. [2007.04.14]
Efavirenz pharmacokinetics in HIV-1-infected children are associated with CYP2B6-G516T polymorphism. [2007.07.01]
Psychosis in a 12-year-old HIV-positive girl with an increased serum concentration of efavirenz. [2007.11.15]
Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26. [2007.11.01]
Efavirenz-induced neurological symptoms in rare homozygote CYP2B6 *2/*2 (C64T). [2007.08]
Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda. [2007.03]
Role of CYP2B6 in stereoselective human methadone metabolism. [2008.03]
CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children. [2007.10.18]
An investigation of potential genetic determinants of propofol requirements and recovery from anaesthesia. [2007.11]
CYP2B6 983T>C polymorphism is prevalent in West Africa but absent in Papua New Guinea: implications for HIV/AIDS treatment. [2007.09]
CYP2B6 genotype alters abstinence rates in a bupropion smoking cessation trial. [2007.09.15]
Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. [2008.04]
Pharmacokinetic interaction between efavirenz and dual protease inhibitors in healthy volunteers. [2008.03]
Pharmacogenomics of antiretrovirals. [2008.06]
Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir. [2008.05]
High prevalence of the CYP2B6 516G-->T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe. [2008.04]
A pharmacokinetic and pharmacogenetic study of efavirenz in children: dosing guidelines can result in subtherapeutic concentrations. [2008]
Detection of low-frequency K103N mutants after unstructured discontinuation of efavirenz in the presence of the CYP2B6 516 TT polymorphism. [2008.12]
Pharmacokinetics of efavirenz when co-administered with rifampin in TB/HIV co-infected patients: pharmacogenetic effect of CYP2B6 variation. [2008.09]
Body mass index can determine the healing of reflux esophagitis with Los Angeles Grades C and D by esomeprazole. [2008.09]
Pharmacogenomics of antiretrovirals. [2008.06]
Successful use of reduced-dose efavirenz in a patient with human immunodeficiency virus infection: case report and review of the literature. [2008.06]
Pharmacogenomics of tamoxifen therapy. [2009.10]
The relationships of ABCB1 3435C>T and CYP2B6 516G>T with high-density lipoprotein cholesterol in HIV-infected patients receiving Efavirenz. [2009.08]
Plasma efavirenz concentrations and the association with CYP2B6-516G >T polymorphism in HIV-infected Thai children. [2009]
Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients. [2009.07]
CYP2B6 (c.516G-->T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients. [2009.04]
Increase of R-/S-methadone enantiomer concentration ratio in serum of patients treated with either nevirapine or efavirenz. [2008.12]
Genetic variation as a predictor of smoking cessation success. A promising preventive and intervention tool for chronic respiratory diseases? [2009.03]
Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals. [2009.05]
CYP2B6 G516T polymorphism but not rifampin coadministration influences steady-state pharmacokinetics of efavirenz in human immunodeficiency virus-infected patients in South India. [2009.03]
Association of drug metabolism gene polymorphisms with toxicities, graft-versus-host disease and survival after HLA-identical sibling hematopoietic stem cell transplantation for patients with leukemia. [2009.03]
Efavirenz induces CYP2B6-mediated hydroxylation of bupropion in healthy subjects. [2008.12.15]
OPRM1 and CYP2B6 gene variants as risk factors in methadone-related deaths. [2010.09]
Long-term efficacy and safety of efavirenz dose reduction to 200 mg once daily in a Caucasian patient with HIV. [2010]
[Methyldopa-induced acute reactive hepatitis in pregnancy, drug-metabolizing capacity of the liver] [2010.03.14]
Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. [2010.03.16]
Nevirapine-induced hepatotoxicity and pharmacogenetics: a retrospective study in a population from Mozambique. [2010.01]
Development of a method to measure methadone enantiomers and its metabolites without enantiomer standard compounds for the plasma of methadone maintenance patients. [2010.07]
Pharmacogenetics of antiretrovirals. [2010.01]
Interactions between herbal medicines and prescribed drugs: an updated systematic review. [2009]
Association of CYP2B6, CYP3A5, and CYP2C19 genetic polymorphisms with sibutramine pharmacokinetics in healthy Korean subjects. [2009.11]
Pharmacokinetics of plasma efavirenz and CYP2B6 polymorphism in southern Chinese. [2009.08]
CYP2B6 G516T genotyping in a UK cohort of HIV-positive patients: polymorphism frequency and influence on efavirenz discontinuation. [2009.09]
Association of cyclophosphamide drug-metabolizing enzyme polymorphisms and chemotherapy-related ovarian failure in breast cancer survivors. [2010.07]
Effect of rifampicin and CYP2B6 genotype on long-term efavirenz autoinduction and plasma exposure in HIV patients with or without tuberculosis. [2011.09]
Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens. [2011.09]
Cytochrome P450 polymorphisms and the response of lupus nephritis to cyclophosphamide therapy. [2011.05]
Cytochrome P450-specific human PBPK/PD models for the organophosphorus pesticides: chlorpyrifos and parathion. [2011.07.11]
The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of substance use and related disorders. Part 2: Opioid dependence. [2011.04]
Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals. [2011.06]
|
